Firefly Bio Debuts with $94M Series A Funding Round

Funding will support its novel platform for treating cancer by merging antibody-drug conjugates with protein degraders.

Author Image

By: Charlie Sternberg

Associate Editor

Firefly Bio, a California-based startup, has debuted on the biotech scene with a Series A funding round of $94 million to support its novel platform for treating cancer by merging antibody-drug conjugates with protein degraders.   Versant Ventures and MPM BioImpact led the Series A along with Decheng Capital and a contribution from Eli Lilly. According to Firefly, its degrader antibody conjugates (DACs) leverage both antibody- drug conjugates (ADCs) and protein degraders. By combining the two ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters